/ /

  • linkedin
  • Increase Font
  • Sharebar

    The latest ocular allergy treatments worth watching

     

    Other therapies

    Trials of other treatments are on-going. Noveome initiated a phase II study of its paracrine modulating compound, ST266, in late 2016 (NCT02978183) and Aldeyra Therapeutics completed a phase II study of their “aldehyde-trap” compound NS2 (NCT02578914) in June 2017.

    The pace of development may have slowed, but this is likely a reflection of the cyclical nature of the drug discovery process. Despite the maturity of the market, there is still an unmet need for ocular allergy therapies and with it a desire to develop new and better treatments.

     

    References

    Gomes PJ. Trends in prevalence and treatment of ocular allergy. Curr Opin Allergy Clin Immunol. 2014 Oct;14(5):451-6.

    Lucas MC, Tan SL. Small-molecule inhibitors of spleen tyrosine kinase as therapeutic agents for immune disorders: will promise meet expectations? Future Med Chem. 2014;6(16):1811-27.

    Cahill KN, Katz HR, Cui J, et al. KIT inhibition by imatinib in patients with severe refractory asthma. N Engl J Med 2017; 376: 1911-20.

    Yoo G, Lee K, Lee DC. Inhibitory effects of 2-oxo-2H-chromen-4-yl 4-methylbenzenesulfonate on allergic inflammatory responses in rat basophilic leukemia cells.  Int Immunopharmacol. 2017; 48:196-202.

    https://www.fda.gov/downloads/biologicsbloodvaccines/allergenics/ucm544382.pdf

     

     

    Paul J. Gomes is vice president for allergy at Ora Inc.

    New Call-to-action

    1 Comment

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    Poll

    View Results